Howard Birndorf, executive chairman of San Diego, Calif.-based Nanogen, will also serve as chief executive officer after the resignation of Randy White, the company’s chief executive officer, and Kieran Gallahue, Nanogen’s president, the firm said last week. White resigned due to health reasons, the company said, while Gallahue will leave Nanogen at the end of the year to accept a position at an undisclosed medical technology firm. Bruce Huebner was named president and chief operating officer. Huebner was a consultant to Nanogen after serving as executive vice president and chief operating officer for Gen-Probe of San Diego.
Adi Hoess was named chief business officer for Berlin-based Jerini last week to begin work on Jan. 1, 2003. Hoess was vice president and general manager of molecular medicine for Carl Zeiss. Previously, he was vice president of licensing and business development for MorphoSys. Hoess has a PhD from Ludwig Maximilian University in Munich. He completed a postdoctorate fellowship at the German Cancer Research Center.
Ale Stavling has been appointed to the board of directors of Cambridge Antibody Technology Group of Cambridge, UK, the company said. Stavling was executive director of AstraZeneca. He replaces Jim Foght who is retiring.
Danial Wayner, acting director general of the National Institute for Nanotechnology of Canada’s National Research Council, has been inducted into the Royal Society of Canada as a fellow. Wayner’s research interest is in the organic modification of semiconductor surfaces.
Psychiatric Genomics added Michael Knable to its scientific advisory board. Knable is medical director for the Stanley Medical Research Institute, which funds research on schizophrenia and bipolar disorder. Psychiatric Genomics has a research collaboration with the SMRI, and the institute also has invested in the company.